Idiopathic distal sensory polyneuropathy: ACTTION diagnostic criteria

Roy Freeman; Jennifer S. Gewandter; Catharina G. Faber; Christopher Gibbons; Simon Haroutounian; Giuseppe Lauria; Todd Levine; Rayaz A. Malik; J. Robinson Singleton; A. Gordon Smith; Josh Bell; Robert H. Dworkin; Eva Feldman; David N. Herrmann; Ahmet Hoke; Noah Kolb; Heikki Mansikka; Anne Louise Oaklander; Amanda Peltier; Michael Polydefkis; Elissa Ritt; James W. Russell; Stephen Sainati; Deborah Steiner; Roi Treister; Nurcan Üçeyler

doi:10.1212/WNL.0000000000010988

Idiopathic distal sensory polyneuropathy: ACTTION diagnostic criteria

Roy Freeman, Jennifer S. Gewandter, Catharina G. Faber, Christopher Gibbons, Simon Haroutounian, Giuseppe Lauria, Todd Levine, Rayaz A. Malik, J. Robinson Singleton, A. Gordon Smith, Josh Bell, Robert H. Dworkin, Eva Feldman, David N. Herrmann, Ahmet Hoke, Noah Kolb, Heikki Mansikka, Anne Louise Oaklander, Amanda Peltier, Michael PolydefkisElissa Ritt, James W. Russell, Stephen Sainati, Deborah Steiner, Roi Treister, Nurcan Üçeyler

Department of Nursing

Research output: Contribution to journal › Article › peer-review

Abstract

ObjectiveTo present standardized diagnostic criteria for idiopathic distal sensory polyneuropathy (iDSP) and its subtypes: idiopathic mixed fiber sensory neuropathy (iMFN), idiopathic small fiber sensory neuropathy (iSFN), and idiopathic large fiber sensory neuropathy (iLFN) for use in research.MethodsThe Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities and Networks (ACTTION) public-private partnership with the Food and Drug Administration convened a meeting to develop consensus diagnostic criteria for iMFN, iSFN, and iLFN. After background presentations, a collaborative, iterative approach was used to develop expert consensus for new criteria.ResultsAn iDSP diagnosis requires at least 1 small fiber (SF) or large fiber (LF) symptom, at least 1 SF or LF sign, abnormalities in sensory nerve conduction studies (NCS) or distal intraepidermal nerve fiber density (IENFD), and exclusion of known etiologies. An iMFN diagnosis requires that at least 1 of the above clinical features is SF and 1 clinical feature is LF with abnormalities in sensory NCS or IENFD. Diagnostic criteria for iSFN require at least 1 SF symptom and at least 1 SF sign with abnormal IENFD, normal sensory NCS, and the absence of LF symptoms and signs. Diagnostic criteria for iLFN require at least 1 LF symptom and at least 1 LF sign with normal IENFD, abnormal sensory NCS, and absence of SF symptoms and signs.ConclusionAdoption of these standardized diagnostic criteria will advance research and clinical trials and spur development of novel therapies for iDSPs.

Original language	English
Pages (from-to)	1005-1014
Number of pages	10
Journal	Neurology
Volume	95
Issue number	22
DOIs	https://doi.org/10.1212/WNL.0000000000010988
State	Published - 1 Dec 2020

Bibliographical note

Funding Information:
This article was reviewed and approved by the Executive Committee of the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership with the US Food and Drug Administration (FDA). Financial support for this project was provided by the ACTTION public-private partnership, which has received research contracts, grants, or other revenue from the FDA, multiple pharmaceutical and device companies, philanthropy, and other sources. The views expressed in this article are those of the authors, and no official endorsement by the FDA or the pharmaceutical and device companies that provided unrestricted grants to support the activities of the ACTTION public-private partnership should be inferred.

Publisher Copyright:
© American Academy of Neurology.

ASJC Scopus subject areas

Clinical Neurology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1212/WNL.0000000000010988

Cite this

Freeman, R., Gewandter, J. S., Faber, C. G., Gibbons, C., Haroutounian, S., Lauria, G., Levine, T., Malik, R. A., Singleton, J. R., Smith, A. G., Bell, J., Dworkin, R. H., Feldman, E., Herrmann, D. N., Hoke, A., Kolb, N., Mansikka, H., Oaklander, A. L., Peltier, A., ... Üçeyler, N. (2020). Idiopathic distal sensory polyneuropathy: ACTTION diagnostic criteria. Neurology, 95(22), 1005-1014. https://doi.org/10.1212/WNL.0000000000010988

@article{8987fc12ef06494dadcea4f5b5e811b7,

title = "Idiopathic distal sensory polyneuropathy: ACTTION diagnostic criteria",

abstract = "ObjectiveTo present standardized diagnostic criteria for idiopathic distal sensory polyneuropathy (iDSP) and its subtypes: idiopathic mixed fiber sensory neuropathy (iMFN), idiopathic small fiber sensory neuropathy (iSFN), and idiopathic large fiber sensory neuropathy (iLFN) for use in research.MethodsThe Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities and Networks (ACTTION) public-private partnership with the Food and Drug Administration convened a meeting to develop consensus diagnostic criteria for iMFN, iSFN, and iLFN. After background presentations, a collaborative, iterative approach was used to develop expert consensus for new criteria.ResultsAn iDSP diagnosis requires at least 1 small fiber (SF) or large fiber (LF) symptom, at least 1 SF or LF sign, abnormalities in sensory nerve conduction studies (NCS) or distal intraepidermal nerve fiber density (IENFD), and exclusion of known etiologies. An iMFN diagnosis requires that at least 1 of the above clinical features is SF and 1 clinical feature is LF with abnormalities in sensory NCS or IENFD. Diagnostic criteria for iSFN require at least 1 SF symptom and at least 1 SF sign with abnormal IENFD, normal sensory NCS, and the absence of LF symptoms and signs. Diagnostic criteria for iLFN require at least 1 LF symptom and at least 1 LF sign with normal IENFD, abnormal sensory NCS, and absence of SF symptoms and signs.ConclusionAdoption of these standardized diagnostic criteria will advance research and clinical trials and spur development of novel therapies for iDSPs.",

author = "Roy Freeman and Gewandter, {Jennifer S.} and Faber, {Catharina G.} and Christopher Gibbons and Simon Haroutounian and Giuseppe Lauria and Todd Levine and Malik, {Rayaz A.} and Singleton, {J. Robinson} and Smith, {A. Gordon} and Josh Bell and Dworkin, {Robert H.} and Eva Feldman and Herrmann, {David N.} and Ahmet Hoke and Noah Kolb and Heikki Mansikka and Oaklander, {Anne Louise} and Amanda Peltier and Michael Polydefkis and Elissa Ritt and Russell, {James W.} and Stephen Sainati and Deborah Steiner and Roi Treister and Nurcan {\"U}{\c c}eyler",

note = "Funding Information: This article was reviewed and approved by the Executive Committee of the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership with the US Food and Drug Administration (FDA). Financial support for this project was provided by the ACTTION public-private partnership, which has received research contracts, grants, or other revenue from the FDA, multiple pharmaceutical and device companies, philanthropy, and other sources. The views expressed in this article are those of the authors, and no official endorsement by the FDA or the pharmaceutical and device companies that provided unrestricted grants to support the activities of the ACTTION public-private partnership should be inferred. Publisher Copyright: {\textcopyright} American Academy of Neurology.",

year = "2020",

month = dec,

day = "1",

doi = "10.1212/WNL.0000000000010988",

language = "English",

volume = "95",

pages = "1005--1014",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "22",

}

Freeman, R, Gewandter, JS, Faber, CG, Gibbons, C, Haroutounian, S, Lauria, G, Levine, T, Malik, RA, Singleton, JR, Smith, AG, Bell, J, Dworkin, RH, Feldman, E, Herrmann, DN, Hoke, A, Kolb, N, Mansikka, H, Oaklander, AL, Peltier, A, Polydefkis, M, Ritt, E, Russell, JW, Sainati, S, Steiner, D, Treister, R & Üçeyler, N 2020, 'Idiopathic distal sensory polyneuropathy: ACTTION diagnostic criteria', Neurology, vol. 95, no. 22, pp. 1005-1014. https://doi.org/10.1212/WNL.0000000000010988

TY - JOUR

T1 - Idiopathic distal sensory polyneuropathy

T2 - ACTTION diagnostic criteria

AU - Freeman, Roy

AU - Gewandter, Jennifer S.

AU - Faber, Catharina G.

AU - Gibbons, Christopher

AU - Haroutounian, Simon

AU - Lauria, Giuseppe

AU - Levine, Todd

AU - Malik, Rayaz A.

AU - Singleton, J. Robinson

AU - Smith, A. Gordon

AU - Bell, Josh

AU - Dworkin, Robert H.

AU - Feldman, Eva

AU - Herrmann, David N.

AU - Hoke, Ahmet

AU - Kolb, Noah

AU - Mansikka, Heikki

AU - Oaklander, Anne Louise

AU - Peltier, Amanda

AU - Polydefkis, Michael

AU - Ritt, Elissa

AU - Russell, James W.

AU - Sainati, Stephen

AU - Steiner, Deborah

AU - Treister, Roi

AU - Üçeyler, Nurcan

N1 - Funding Information: This article was reviewed and approved by the Executive Committee of the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership with the US Food and Drug Administration (FDA). Financial support for this project was provided by the ACTTION public-private partnership, which has received research contracts, grants, or other revenue from the FDA, multiple pharmaceutical and device companies, philanthropy, and other sources. The views expressed in this article are those of the authors, and no official endorsement by the FDA or the pharmaceutical and device companies that provided unrestricted grants to support the activities of the ACTTION public-private partnership should be inferred. Publisher Copyright: © American Academy of Neurology.

PY - 2020/12/1

Y1 - 2020/12/1

N2 - ObjectiveTo present standardized diagnostic criteria for idiopathic distal sensory polyneuropathy (iDSP) and its subtypes: idiopathic mixed fiber sensory neuropathy (iMFN), idiopathic small fiber sensory neuropathy (iSFN), and idiopathic large fiber sensory neuropathy (iLFN) for use in research.MethodsThe Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities and Networks (ACTTION) public-private partnership with the Food and Drug Administration convened a meeting to develop consensus diagnostic criteria for iMFN, iSFN, and iLFN. After background presentations, a collaborative, iterative approach was used to develop expert consensus for new criteria.ResultsAn iDSP diagnosis requires at least 1 small fiber (SF) or large fiber (LF) symptom, at least 1 SF or LF sign, abnormalities in sensory nerve conduction studies (NCS) or distal intraepidermal nerve fiber density (IENFD), and exclusion of known etiologies. An iMFN diagnosis requires that at least 1 of the above clinical features is SF and 1 clinical feature is LF with abnormalities in sensory NCS or IENFD. Diagnostic criteria for iSFN require at least 1 SF symptom and at least 1 SF sign with abnormal IENFD, normal sensory NCS, and the absence of LF symptoms and signs. Diagnostic criteria for iLFN require at least 1 LF symptom and at least 1 LF sign with normal IENFD, abnormal sensory NCS, and absence of SF symptoms and signs.ConclusionAdoption of these standardized diagnostic criteria will advance research and clinical trials and spur development of novel therapies for iDSPs.

AB - ObjectiveTo present standardized diagnostic criteria for idiopathic distal sensory polyneuropathy (iDSP) and its subtypes: idiopathic mixed fiber sensory neuropathy (iMFN), idiopathic small fiber sensory neuropathy (iSFN), and idiopathic large fiber sensory neuropathy (iLFN) for use in research.MethodsThe Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities and Networks (ACTTION) public-private partnership with the Food and Drug Administration convened a meeting to develop consensus diagnostic criteria for iMFN, iSFN, and iLFN. After background presentations, a collaborative, iterative approach was used to develop expert consensus for new criteria.ResultsAn iDSP diagnosis requires at least 1 small fiber (SF) or large fiber (LF) symptom, at least 1 SF or LF sign, abnormalities in sensory nerve conduction studies (NCS) or distal intraepidermal nerve fiber density (IENFD), and exclusion of known etiologies. An iMFN diagnosis requires that at least 1 of the above clinical features is SF and 1 clinical feature is LF with abnormalities in sensory NCS or IENFD. Diagnostic criteria for iSFN require at least 1 SF symptom and at least 1 SF sign with abnormal IENFD, normal sensory NCS, and the absence of LF symptoms and signs. Diagnostic criteria for iLFN require at least 1 LF symptom and at least 1 LF sign with normal IENFD, abnormal sensory NCS, and absence of SF symptoms and signs.ConclusionAdoption of these standardized diagnostic criteria will advance research and clinical trials and spur development of novel therapies for iDSPs.

UR - http://www.scopus.com/inward/record.url?scp=85097004519&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000010988

DO - 10.1212/WNL.0000000000010988

M3 - Article

C2 - 33055271

AN - SCOPUS:85097004519

SN - 0028-3878

VL - 95

SP - 1005

EP - 1014

JO - Neurology

JF - Neurology

IS - 22

ER -

Idiopathic distal sensory polyneuropathy: ACTTION diagnostic criteria

Abstract

Bibliographical note

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this